Option Care Health Inc. (OPCH)
Should Value Investors Buy Option Care Health (OPCH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Option Care Health, Inc. (OPCH) Q2 2024 Earnings Call Transcript
Option Care Health, Inc. (NASDAQ:OPCH ) Q2 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Nicole Maggio - Senior Vice President of Finance John Rademacher - President & CEO Mike Shapiro - CFO Conference Call Participants Lisa Gill - JPMorgan Constantine Davides - Citizens JMP Matt Larew - William Blair David MacDonald - Truist Securities Pito Chickering - Deutsche Bank Brian Tanquilut - Jefferies Joanna Gajuk - Bank of America Michael Petusky - Barrington Research Operator Good day, and thank you for standing by. Welcome to the Option Care Health Second Quarter 2024 Earnings Conference Call.
Option Care (OPCH) Q2 Earnings and Revenues Top Estimates
Option Care (OPCH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.63 per share a year ago.
The 3 Highest-Rated Medical Stocks You Can Buy Today
The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.
Option Care (OPCH) Upgraded to Strong Buy: Here's Why
Option Care (OPCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Option Care Health: A Deep Dive Into Its Market Dominance
Option Care Health, the largest alternative infusion provider, is poised to benefit from the shift to home-based health and the growing specialty pharmaceuticals market. Despite the 13% drop YTD, OPCH's fundamentals have only improved and has continued beating quarterly revenue and EBITDA estimates for the past 13 earnings. I believe the new Medicare home infusion policies and continued site-of-care initiatives by insurers are likely to further enhance OPCH's financials and competitive advantage.
